γ-Secretase as a therapeutic target for treatment of Alzheimer's disease

Current Pharmaceutical Design

Volumn 12, Issue 6, 2006, Pages 661-670

  Tomita, Taisuke ^a   Iwatsubo, Takeshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

secretase; A ; Alzheimer's disease; Amyloid; Aspartic protease; Intramembrane proteolysis; Presenilin; Protease inhibitor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BUTYROLACTONE; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IBUPROFEN; IMATINIB; INDOMETACIN; ISOCOUMARIN DERIVATIVE; JLK 6; KENPAULLONE; L 685458; LITHIUM CHLORIDE; LY 411575; N [N (3,5 DIFLUOROPHENACETYL)ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PLACEBO; PRESENILIN 1; PRESENILIN 2; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; ROFECOXIB; ROSCOVITINE; SULFONAMIDE; SULINDAC SULFIDE; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; ENZYME INHIBITOR; PROTEINASE; SECRETASE;

AGING; ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; DEMENTIA; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE;

EID: 33645280382     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474206     Document Type: Review

References (136)

1. Selkoe DJ. Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease. J Clin Invest 2002; 110: 1375-81.
2. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002; 1: 859-6.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
4. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimers disease. Biochemistry 1993; 32: 4693-7.
5. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45-53.
6. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez tur J, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-3.
7. Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997; 94: 2025-30.
8. De Strooper B, Saftig P, Craessaerts K, Vandertichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-90.
9. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2000; 2: 461-2.
10. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, et al. Presenilins are required for γ-secretase cleavage of βAPP and transmembrane cleavage of Notch-1. Nat Cell Biol 2000; 2: 463-5.
11. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996; 17: 181-90.
12. Ratovitski T, Slunt HH, Thinakaran G, Price DL, Sisodia SS, Borchelt DR. Endoproteolytic processing and stabilization of wild-type and mutant presenilin. J Biol Chem 1997, 272: 24536-41.
13. Seeger M, Nordstedt C, Petanceska S, Kovacs DM, Gouras GK, Hahne S, et al. Evidence for phosphorylation and oligomeric assembly of presenilin 1. Proc Natl Acad Sci USA 1997; 94: 5090-4.
14. Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, et al. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. J Biol Chem 1998; 273: 3205-11.
15. Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L, et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin. J Biol Chem 1998; 273: 16470-5.
16. Tomita T, Tokuhiro S, Hashimoto T, Aiba K, Saido TC, Maruyama K, et al. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid β peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Aβ42. J Biol Chem 1998; 273: 21153-60.
17. Saura CA, Tomita T, Davenport F, Harris CL, Iwatsubo T, Thinakaran G. Evidence that intramolecular associations between presenilin domains are obligatory for endoproteolytic processing. J Biol Chem 1999; 274: 13818-23.
18. Saura CA, Tomita T, Soriano S, Takahashi M, Leem JY, Honda T, et al. The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced Aβ42 production mediated by familial early onset alzheimer's disease-linked PS variants. J Biol Chem 2000; 275: 17136-42.
19. Tomita T, Takikawa R, Koyama A, Morohashi Y, Takasugi N, Saido TC, et al. C terminus of presenilin is required for overproduction of amyloidogenic Aβ42 through stabilization and endoproteolysis of presenilin. J Neurosci 1999; 19: 10627-34.
20. Tomita T, Watabiki T, Takikawa R, Morohashi Y, Takasugi N, Kopan R, et al. The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation and γ-secretase activities of presenilins. J Biol Chem 2001; 276: 33273-81.
21. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999; 398: 513-7.
22. Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid β-peptide production and notch signaling. J Biol Chem 1999; 274: 28669-73.
23. Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, et al. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol 2000; 2: 848-51.
24. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 2002; 296: 2215-8.
25. Haass C, Steiner H. Alzheimer disease γ-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 202; 12: 556-62.
26. Li YM, Lai MT, Xu M, Huang Q, DiMuzio Mower J, Sardana MK, et al. Presenilin 1 is linked with γ-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 2000; 97: 6138-43.
27. Li YM, Xu M, Lai MT, Huang Q, Castro X, DiMuzio Mower J, et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000; 405: 689-94.
28. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, et al. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol 2000; 2: 428-34.
29. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, et al. Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J Biol Chem 2000; 275: 34086-91.
30. Selkoe D, Kopan R. Notch and presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. in press.
31. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998; 393: 382-6.
32. Levitan D, Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 1995; 377: 351-4.
33. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 1997; 387: 288-92.
34. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997; 89: 629-39.
35. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 1999; 96: 11872-7.
36. Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev 1999; 13: 2801-10.
37. Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 1999; 398: 522-5.
38. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-22.
39. Ikeuchi T, Sisodia SS. The notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent "γ-secretase" cleavage. J Biol Chem 2003; 278: 7751-4.
40. Bland CE, Kimberly P, Rand MD. Notch-induced proteolysis and nuclear localization of the Delta ligand. J Biol Chem 2003; 278: 13607-10.
41. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, et al. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and γ-secretase. Proc Natl Acad Sci USA 2003; 100: 7638-43.
42. LaVoie MJ, Selkoe, DJ. The notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin /γ-secretase and release signaling fragments. J Biol Chem 2003; 278: 34427-37.
43. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Aβ-like peptide. J Biol Chem 2002; 277: 44754-9.
44. Murakami D, Okamoto J, Nagano O, Kawano Y, Tomita T, Iwatsubo T, et al. Presenilin-dependent γ-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 2003; 22: 1511-6.
45. Ni CY, Murphy MP, Golde TE, Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294: 2179-81.
46. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, et al. Presenilin-dependent γ-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 2002; 277: 6318-23.
47. Marambaud P, Shioi J, Serban O, Georgakopoulos A, Sarner S, Nagy V, et al. A presenilin-1/γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002; 21: 1948-56.
48. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, et al. A CBP binding transcriptional repressor produced by the PS1/ε-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003; 114: 635-45.
49. May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem 2002; 277: 18736-43.
50. Kim DY, Ingano LA, Kovacs DM. Nectin-1α, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/γ-secretase-like cleavage. J Biol Chem 2002; 277: 49976-81.
51. Bao J, Wolpowitz D, Role LW, Talmage DA. Back signaling by the Nrg-1 intracellular domain. J Cell Biol 2003; 161: 1133-41.
52. Taniguchi Y, Kim SH, Sisodia SS. Presenilin-dependent "γ-secretase" processing of deleted in colorectal cancer (DCC). J Biol Chem 2003; 278: 30425-8.
53. Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecterson LC. Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. J Neurosci 2003; 23: 5425-36.
54. Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, et al. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem 2003; 278: 42161-9.
55. Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G. Syndecan 3 intramembrane proteolysis is presenilin/ γ-secretase-dependent and modulates cytosolic signaling. J Biol Chem. in press.
56. Struhl G, Adachi A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol Cell 2000; 6: 625-36.
57. Cao X, Sudhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001; 293: 115-20.
58. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, et al. Presenilin-dependent γ-secretase processing of β-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2001; 2: 835-41.
59. Gu Y, Misonou H, Sato T, Dohmae N, Takio K, Ihara Y. Distinct intramembrane cleavage of the β-amyloid precursor protein family resembling γ-secretase-like cleavage of Notch. J Biol Chem 2001; 276: 35235-8.
60. Okochi M, Steiner H, Fukumori A, Tanii H, Tomita T, Tanaka T, et al. Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. EMBO J 2002; 21: 5408-16.
61. Yu C, Kim SH, Ikeuchi T, Xu H, Gasparini L, Wang R, et al. Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment γ. Evidence for distinct mechanisms involved in γ-secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 2001; 276: 43756-60.
62. Fortini ME. γ-secretase-mediated proteolysis in cell-surface-receptor signaling. Nat Rev Mol Cell Biol 2002; 3: 673-84.
63. Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, et al. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem 1997; 272: 28415-22.
64. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature 2000; 407: 48-54.
65. Chen F, Yu G, Arawaka S, Nishimura M, Kawarai T, Yu H, et al. Nicastrin binds to membrane-tethered Notch. Nat Cell Biol 2001; 3: 751-4.
66. Goutte C, Hepler W, Mickey KM, Priess JR. aph-2 encodes a novel extracellular protein required for GLP-1-mediated signaling. Development 2000; 127: 2481-92.
67. Levitan D, Yu G, St George-Hyslop P, Goutte C. APH-2/nicastrin functions in LIN-12/Notch signaling in the Caenorhabditis elegans somatic gonad. Dev Biol 2001; 240: 654-61.
68. Chung HM, Struhl G. Nicastrin is required for Presenilin-mediated transmembrane cleavage in Drosophila. Nat Cell Biol 2001; 3: 1129-32.
69. Hu Y, Ye Y, Fortini ME. Nicastrin is required for γ-secretase cleavage of the Drosophila Notch receptor. Dev Cell 2002, 2: 69-78.
70. Lopez Schier H, St Johnston D. Drosophila nicastrin is essential for the intramembranous cleavage of notch. Dev Cell 2002; 2: 79-89.
71. Li T, Ma G, Cai H, Price DL, Wong PC. Nicastrin is required for assembly of presenilin/γ-secretase complexes to mediate Notch signaling and for processing and trafficking of β-amyloid precursor protein in mammals. J Neurosci 2003; 23: 3272-7.
72. Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, et al. Positive and negative regulation of the γ-Secretase activity by Nicastrin in a murine model. J Biol Chem 2003; 278: 33445-9.
73. Leem JY, Vijayan S, Han P, Cai D, Machura M, Lopes KO, et al. Presenilin 1 is required for maturation and cell surface accumulation of nicastrin. J Biol Chem 2002; 277: 19236-40.
74. Tomita T, Katayama R, Takikawa R, Iwatsubo T. Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments. FEBS Lett 2002; 520: 117-21.
75. Edbauer D, Winkler E, Haass C, Steiner H. Presenilin and nicastrin regulate each other and determine amyloid β-peptide production via complex formation. Proc Natl Acad Sci USA 2002; 99: 8666-71.
76. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Complex N-linked glycosylated nicastrin associates with active γ-secretase and undergoes tight cellular regulation. J Biol Chem 2002; 277: 35113-7.
77. Yang DS, Tandon A, Chen F, Yu G, Yu H, Arawaka S, et al. Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 2002; 277: 28135-42.
78. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, et al. Activity-dependent isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate. Proc Natl Acad Sci USA 2002; 99: 2720-5.
79. Kaether C, Lammich S, Edbauer D, Ertl M, Rietdorf J, Capell A, et al. Presenilin-1 affects trafficking and processing of βAPP and is targeted in a complex with nicastrin to the plasma membrane. J Cell Biol 2002; 158: 551-61.
80. Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 2002; 99: 775-9.
81. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. aph-1 and pen-2 are required for Notch pathway signaling, γ-secretase cleavage of βAPP, and presenilin protein accumulation. Dev Cell 2002; 3: 85-97.
82. Steiner H, Winkler E, Edbauer D, Prokop S, Basset G, Yamasaki A, et al. PEN-2 is an integral component of the γ-secretase complex required for coordinated expression of presenilin and nicastrin. J Biol Chem 2002; 277: 39062-5.
83. Lee SF, Shah S, Li H, Yu C, Han W, Yu G. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-β precursor protein and Notch. J Biol Chem 2002; 277: 45013-9.
84. Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, et al. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem 2003; 278: 7850-4.
85. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, et al. The role of presenilin cofactors in the γ-secretase complex. Nature 2003; 422: 438-41.
86. LaVoie MJ, Fraering PC, Ostaszewski BL, Ye W, Kimberly WT, Wolfe MS, et al. Assembly of the γ-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and Nicastrin. J Biol Chem 2003; 278: 37213-22.
87. Hu Y, Fortini ME. Different cofactor activities in γ-secretase assembly: evidence for a nicastrin-Aph-1 subcomplex. J Cell Biol 2003; 161: 685-90.
88. Gu Y, Chen F, Sanjo N, Kawarai T, Hasegawa H, Duthie M, et al. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin-nicastrin complexes. J Biol Chem 2003; 278: 7374-80.
89. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA 2003; 100: 6382-7.
90. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of γ-secretase activity. Nat Cell Biol 2003; 5: 486-8.
91. Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, Naslund J. Partial purification and characterization of γ-secretase from post mortem human brain. J Biol Chem. in press.
92. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active γ-Secretase complex. Neuron 2003; 38: 9-12.
93. Schmidt B. Aspartic proteases involved in Alzheimer's disease. Chembiochem 2003; 4: 366-78.
94. Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. A substrate-based difluoroketone selectively inhibits Alzheimer's γ-secretase activity. J Med Chem 1998; 41: 6-9.
95. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685, 458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid b-protein precursor γ-secretase activity. Biochemistry 2000; 39: 8698-704.
96. Lewis HD, Perez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, et al. Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and bAPP Cleavages. Biochemistry 2003; 42: 7580-6.
97. Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, et al. A presenilin dimer at the core of the γ-secretase enzyme: Insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA. in press.
98. Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JD, Li YM, et al. In vitro characterization of the presenilin-dependent γ-secretase complex using a novel affinity ligand. Biochemistry 2003; 42: 8133-42.
99. Tian G, Sobotka Briner CD, Zysk J, Liu X, Birr C, Sylvester MA, et al. Linear non-competitive inhibition of solubilized human γ-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem 2002; 277: 31499-505.
100. Tian G, Ghanekar SV, Aharony D, Shenvi AB, Jacobs RT, Liu X, et al. The mechanism of γ-secretase. Multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J Biol Chem. in press.
101. Kornilova AY, Das C, Wolfe MS. Differential effects of inhibitors on the γ-secretase complex: mechanistic implications. J Biol Chem 2003; 278: 16470-3.
102. Berezovska O, Ramdya P, Skoch J, Wolfe MS, Bacskai BJ, Hyman BT. Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-γ-secretase complex in cells demonstrated by fluorescence lifetime imaging. J Neurosci 2003; 23: 4560-6.
103. Das C, Berezovska O, Diehl TS, Genet C, Buldyrev I, Tsai JY, et al. Designed helical peptides inhibit an intramembrane protease. J Am Chem Soc 2003; 125: 11794-5.
104. Micchelli CA, Esler WP, Kimberly WT, Jack C, Berezovska O, Kornilova A, et al. γ-Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J 2002; 17: 79-81.
105. Geling A, Steiner H, Willem M, Bally Cuif L, Haass C. A γ-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002; 3: 688-94.
106. Kimberly WT, Esler WP, Ye W, Ostaszewski BL, Gao J, Diehl T, et al. Notch and the amyloid precursor protein are cleaved by similar γ-secretase(s). Biochemistry 2003; 42: 137-44.
107. Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS, et al. γ-Secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 2001; 98: 7487-91.
108. Doerfler P, Shearman MS, Perlmutter RM. Presenilin-dependent γ-secretase activity modulates thymocyte development. Proc Natl Acad Sci USA 2001; 98: 9312-7.
109. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-81.
110. Lanz TA, Himes CS, Pallante G, Adams LA, Yamazaki S, Amore BM, et al. The γ-secretase inhibitor, DAPT, reduces Aβ levels in vivo in plasma and CSF in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305: 864-71.
111. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, et al. Adipsin: a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J Biol Chem. in press.
112. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 2003; 23: 8844-53.
113. Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJ, et al. Fenchylamine sulfonamide inhibitors of amyloid β peptide production by the γ-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J Med Chem 2000; 43: 2297-9.
114. Petit A, Bihel F, da Costa CA, Pourquie O, Checler F, Kraus JL. New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nat Cell Biol 2001; 3: 507-11.
115. Esler WP, Das C, Campbell WA, Kimberly WT, Kornilova AY, Diehl TS, et al. Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase. Nat Cell Biol 2002; 4: E110-1.
116. Bihel F, Quelever G, Lelouard H, Petit A, Alves da Costa C, Pourquie O, et al. Synthesis of new 3-alkoxy-7-amino-4-chloroisocoumarin derivatives as new β-amyloid peptide production inhibitors and their activities on various classes of protease. Bioorg Med Chem 2003; 11: 3141-52.
117. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003; 423: 435-9.
118. Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li YM, et al. Gleevec inhibits β-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA. in press.
119. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003; 163: 83-95.
120. Zandi PP, Breitner JCS. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001; 22: 811-7.
121. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
122. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-26.
123. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
124. Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J Neurochem 2002; 83: 1009-12.
125. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003; 278: 30748-54.
126. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-14.
127. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001; 22: 983-91.
128. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002; 22: 2246-54.
129. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, et al Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003; 23: 7504-9.
130. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Aβ42 in vivo. J Clin Invest 2003; 112: 440-9.
131. Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, et al. Sulindac sulfide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ42 generation. J Biol Chem 2003; 278: 18664-70.
132. Weggen S, Eriksen JL, Sagi SA, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β 42 production by direct modulation of γ-secretase activity. J Biol Chem 2003; 278: 31831-7.
133. Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NFκB, do not reduce amyloid β 42 production. J Biol Chem 2003; 278: 31825-30.
134. Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr Pharm Design 2004; 10(28): 3505-24.
135. Asanuma M, Miyazaki I, Ogawa N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Design 2004; 10(6): 695-700.
136. Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr Pharm Design 2004; 10(25): 3167-75.